Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States

Relieving the three types of endometriosis pain and reducing cost are the most important considerations for women when selecting GnRH agonist/antagonist treatment. Women with endometriosis strongly prefer a medication that can be safely taken for longer periods of time, takes effect within a few menstrual cycles, and can reduce endometriosis-related fatigue. Findings can inform discussions between patients and healthcare providers to better align endometriosis treatment decision-making with patients' individual needs and preferences.

Authors

Institutions

Publication Details

Journal
Women s Health
Published
2025-09-01
DOI
https://doi.org/10.1177/17455057251331700
Primary Topic
Endometriosis Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States

Kathleen Marie Beusterien, Brett Hauber, Martine C. Maculaitis, Nicole T. Ansani et al.
Women s Health
Endometriosis Research and Treatment
article

Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States

Kathleen Marie Beusterien, Brett Hauber, Martine C. Maculaitis, Nicole T. Ansani, Paul Cislo, Ruth Kim, Elke Hunsche
article en

Abstract

Relieving the three types of endometriosis pain and reducing cost are the most important considerations for women when selecting GnRH agonist/antagonist treatment. Women with endometriosis strongly prefer a medication that can be safely taken for longer periods of time, takes effect within a few menstrual cycles, and can reduce endometriosis-related fatigue. Findings can inform discussions between patients and healthcare providers to better align endometriosis treatment decision-making with patients' individual needs and preferences.

Women s HealthVol. 21
Oracle (United States) (US), Pfizer (United States) (US), Amgen (Switzerland) (CH), Statistical Research (United States) (US)
Openalex Percentile: Top 69%
Endometriosis Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.